Now Booking Free 30-minute strategy call For clinic founders and owners See if you qualify
Clinic laboratory work area, for clinic owners reviewing the FDA status of exosome products

Exosomes and the FDA: What Every Clinic Owner Needs to Know

October 05, 2026•7 min read

Why There Is No Compliant Way to Offer Exosome Therapy, and Why ACG Steers Clients Away From It

The Answer Is Shorter Than People Expect

There are currently no FDA-approved exosome products. That sentence is the FDA's own, from its December 2019 Public Safety Notification on Exosome Products, and the agency has repeated it to patients and cited the notification in warning letters since.

Not a limited approval. Not approval for some indications. None, for any therapeutic use.

This post explains what that means for a clinic owner, why the workarounds do not work, and why ACG does not help clients build a business around exosome therapy.

This is one of five areas covered in our guide to regenerative health clinic compliance.

This post is educational and does not constitute legal advice. Regulatory requirements vary by state and change over time. Clinic owners should work with healthcare counsel admitted in their state before making structural, sourcing, or marketing decisions.

How the FDA Classifies Exosomes

Exosomes are extracellular vesicles: small particles cells release that carry proteins, lipids, and genetic material. The underlying science is a legitimate and active research field. That is not in dispute and is not the issue.

The issue is regulatory classification. As a general matter, exosomes used to treat diseases or conditions in humans are regulated as drugs and biological products under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act, and are subject to premarket review and approval requirements.

That means an exosome product intended for therapeutic use requires a biologics license before it can be lawfully marketed. Licenses are issued only after demonstrating the product is safe, pure, and potent. No exosome product has completed that process.

The FDA has also addressed a common argument from clinics. Its notification states directly that clinics may claim these products do not fall under the regulatory provisions for drugs and biological products, and that this is "simply untrue."

Why This Notification Exists

The FDA issued its exosome notification in December 2019 following multiple reports of serious adverse events experienced by patients in Nebraska treated with unapproved products marketed as containing exosomes. The reports came to the agency through the CDC among others, and were addressed in coordination with state health authorities.

This context matters for clinic owners weighing the risk. The regulatory position is not a technicality awaiting modernization. The notification itself followed reports of serious harm to patients.

The FDA makes the same point to patients in its consumer alert on stem cell and exosome products, which means a clinic's prospective patients may encounter it independently.

The Workarounds Do Not Work

"It is for cosmetic use"

The FDA has rejected this directly. In a 2023 warning letter to an exosome manufacturer, the agency noted the company had stated during inspection that its exosome products were for cosmetic use, but continued marketing them to treat conditions such as skin damage. The products therefore continued to meet the definition of a drug and a biological product. Intended use is established by how a product is marketed, not by what the company calls it.

"We apply it topically, not by injection"

Topical application onto skin whose barrier has been intentionally broken (after microneedling, for instance) is not equivalent to applying a cosmetic to intact skin. The regulatory analysis follows the product's intended use, not the word used to describe the procedure, and the FDA's October 2025 consumer update on microneedling says it has not cleared any microneedling device for use with another product.

"Our supplier says it is compliant"

Supplier assurances are not a defense, and exosome suppliers have themselves received FDA warning letters. In the agency's letters to these suppliers between 2024 and 2025, including the letters to New Life Medical Services and Evolutionary Biologics, the recurring conclusion is that the products are unapproved new drugs and unlicensed biological products. A clinic buying from a supplier the FDA has warned has not inherited the supplier's position. It has adopted the supplier's risk.

Where the Enforcement Pressure Is Going

The letters have continued and broadened. In September 2025 a warning letter to New Life Medical Services, covering umbilical cord derived and exosome-based products, found them unapproved new drugs and unlicensed biological products and directed the company's attention to the same public safety notification, issued nearly six years earlier. In May 2026 the FDA's warning letter to Blue Horizon International, which marketed a cord blood stem cell therapy and an exosome therapy derived from Wharton's jelly, found that neither product had an approved biologics license or an IND in effect.

State medical boards have moved in parallel. In a 2017 survey by the Federation of State Medical Boards, 17 of the 51 boards that responded had investigated complaints against physicians over stem cell and related therapies, and eight of those boards had taken disciplinary action. That places the medical director's license at issue alongside the clinic's business exposure.

What This Means for a Clinic That Already Offers It

Some clinic owners reading this already have exosomes on their service menu, often because a supplier presented them as an established regenerative offering and no one involved raised the regulatory question.

The practical steps are straightforward, though not comfortable. Stop offering the service and remove it from the website, social profiles, intake materials, and any schema or structured data that references it: FDA warning letters routinely cite company websites as evidence of intended use, and stale marketing is still marketing. Speak with healthcare counsel about the exposure created by past offerings. Review whether your supplier has received FDA correspondence, since in 2025 the FDA asked one supplier for a customer list for each of two products, one of them exosome-based. And discuss the situation with your medical director directly, because their licensure is implicated alongside the clinic's business exposure.

The clinics that handle this well treat it as a correction rather than a crisis. A clinic that stopped promptly on learning the regulatory status is in a materially different position from one that continued after being informed. If a warning letter has already arrived, see how a clinic responds to an FDA warning letter.

ACG's Position

Straightforwardly: ACG does not help clients build a business around exosome therapy.

There is no FDA-approved exosome product and no compliant way to offer exosome therapy as a clinic service. ACG helps clients walk defensible lines. It does not explain how to do something that is prohibited, and it does not build revenue models on services that expose a client to federal enforcement and their medical director to licensure risk.

Clinic owners occasionally hear this as ACG being conservative. The more accurate reading is that a consultant willing to help you build around exosomes is a consultant who will be similarly relaxed about the next question, on a topic where you may not know enough to catch it.

The regenerative services that are defensible are covered elsewhere on this blog: autologous procedures that qualify for the same surgical procedure exception (21 CFR 1271.15(b)), in our guide on how to open a stem cell clinic; prescriber-directed peptide therapy, limited to compounds a pharmacy may lawfully compound; and hormone optimization.

If you are planning a new clinic, our team helps founders launch a clinic without services that draw enforcement; if cellular procedures are in the plan, start with what it takes to open a stem cell clinic. To discuss a compliant service menu for your clinic, book a free 30-minute strategy call.

Frequently Asked Questions

Are exosomes legal to use in a clinic?

As of October 25, 2026, no exosome product is FDA-approved. Exosomes used to treat diseases or conditions in humans are regulated as drugs and biological products requiring premarket approval, and no product has received it. Clinics offering exosome therapy are marketing unapproved biologics.

What about exosomes used in a clinical trial?

Investigational use under an Investigational New Drug application (IND) that is in effect, within a properly conducted clinical trial, is a distinct legal pathway from commercial service delivery. It is a research undertaking with protocol, oversight, and reporting obligations, and an investigational product cannot be promoted or sold commercially (21 CFR 312.7). It is not a business model for a cash-pay clinic, and not what clinics marketing exosome therapy are typically doing.

Many clinics near me offer this. Does that change the analysis?

No. Widespread practice is not evidence of legality. The FDA's notification specifically describes clinics across the country offering exosome products and deceiving patients with unsubstantiated claims. Prevalence is what the notification warns about, not what excuses it.

Is the science behind exosomes fake?

No, and it is worth separating the two questions. Extracellular vesicle research is legitimate and active, and some products have entered clinical trials under IND applications. The problem is the gap between research interest and regulatory approval. A product being scientifically interesting does not make it lawful to sell.

Written by Nova, Senior Content Strategist at Altos Consulting Group.

Nova S.

Nova S.

Nova is Senior Content Strategist at Altos Consulting Group, building the content that helps founders open and grow regenerative health clinics.

Back to Blog
Built by operators. Our team has launched hundreds of clinics.